Damora Therapeutics, Inc.

Listed Company

DMRACIK 0001800315NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-209.84M

Total Assets

$260.53M

Equity

$240.38M

Shares Out

61.55M

Op. Cash Flow

$-6.70M

DMRA$31.34+21.99% · past 4 monthsDBEQ Basic

Daily closing prices

Business

Damora Therapeutics is a biopharmaceutical company developing targeted therapies for hematologic disorders, particularly myeloproliferative neoplasms. The company's lead product candidate, DMR-001, is a monoclonal antibody designed to target mutant calreticulin for the treatment of essential thrombocythemia and myelofibrosis. Damora holds options to license two additional mutCALR-targeting antibodies, DMR-002 and DMR-003, under an agreement with Paragon Therapeutics. Development activities are conducted in the United States and other key markets.

Summary from 10-K filed 2026-03-19

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	27	6	24	48	38
Acquired in-process research and development	174	4	—	—	—
General and administrative	10	10	13	13	14
Restructuring costs	0	968,000	3	—	—
Total operating expenses	211	22	40	61	52
Loss from operations	−211	−22	−40	−61	−52
Interest income, net	1	844,000	2	722,000	156,000
Foreign exchange transaction gain (loss), net	−84,000	18,000	−197,000	−1	319,000
Total other income, net	1	862,000	2	−417,000	475,000
Loss before income tax expense	−210	−21	−38	—	—
Income tax expense	−50,000	−41,000	0	—	—
Net loss	−210	−21	−38	−62	−52
Net loss per share, basic, common stock	3.98	−18.53	−36.08	−2.43	−2.05
Net loss per share, diluted, common stock	3.98	−18.53	−36.08	−2.43	−2.05
Weighted-average number of shares used in computing net loss per common share, basic	1	1	1	25	25
Weighted-average number of shares used in computing net loss per common share, diluted	1	1	1	25	25
Currency translation gain (loss)	705,000	−283,000	393,000	265,000	−917,000
Other comprehensive income (loss), net of tax	705,000	−283,000	624,000	76,000	−994,000
Total comprehensive loss	−209	−22	−38	−62	−53

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	258	14	21	33	63
Prepaid expenses and other current assets	3	3	4	4	10
Total current assets	260	17	37	64	110
Operating lease right-of-use asset	68,000	73,000	247,000	810,000	834,000
Equipment, net	36,000	57,000	78,000	357,000	203,000
Other assets, noncurrent	0	163,000	1	2	2
Total assets	261	17	38	73	122
Accounts payable	444,000	377,000	2	3	2
Accrued expenses and other current liabilities	2	820,000	4	8	3
Total current liabilities	20	1	6	11	5
Operating lease liabilities, noncurrent	53,000	61,000	66,000	328,000	448,000
Other liabilities, noncurrent	28,000	43,000	—	—	—
Total liabilities	20	1	6	11	5
Commitments and contingencies (Note 11)	—	—	—	—	—
Mezzanine equity, Preferred stock, par value of $0.00001 per share; 10,000,000 shares authorized at December 31, 2025 and 2024; 159 shares issued and outstanding as of December 31, 2025 and 161 shares issued or outstanding as of December 31, 2024	1	1	—	—	—
Common stock, par value of $0.00001 per share; 500,000,000 shares authorized at December 31, 2025 and 2024; 1,597,321 and 1,316,989 shares issued and outstanding at December 31, 2025 and 2024, respectively	—	—	—	—	—
Additional paid-in capital	311	292	288	280	274
Accumulated deficit	−487	−278	−256	−218	−156
Accumulated other comprehensive income	802,000	97,000	380,000	−244,000	−320,000
Total stockholders equity	240	16	32	62	117
Total liabilities and stockholders equity	261	17	38	73	122

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net loss	−210	−21	−38	−62	−52
Depreciation of equipment	22,000	21,000	300,000	42,000	20,000
Stock-based compensation	998,000	3	5	6	4
Issuance of common stock in connection with vesting of restricted stock units	39,000	93,000	—	—	—
Issuance of preferred and common stock in connection with an Asset Purchase Agreement	—	2	—	—	—
In-process research and development costs in connection with Damora Asset Acquisition	174	—	—	—	—
Issuance of Paramora Warrant, net of cost assumed in Damora Asset Acquisition	9	—	—	—	—
Amortization of premiums and discounts on marketable securities	—	70,000	−431,000	566,000	1
Amortization of right of use lease asset	12,000	160,000	561,000	448,000	421,000
Accretion of lease liability	6,000	10,000	46,000	58,000	75,000
Prepaid expenses and other current assets	−138,000	954,000	65,000	6	−4
Other assets, noncurrent	166,000	970,000	1	−257,000	−866,000
Accounts payable	51,000	−1	−2	2	−1
Accrued expenses and other current liabilities	1	−3	−3	5	274,000
Related party accounts payable and other current liabilities	17	—	—	—	—
Operating lease liabilities	−20,000	−170,000	−600,000	−523,000	−513,000
Other liabilities, noncurrent	−15,000	43,000	—	—	—
Net cash used in operating activities	−7	−19	−37	−43	−52
Damora Asset Acquisition costs, net of cash assumed	−17	—	—	—	—
Proceeds from sale of marketable securities	—	12	48	57	36
Net cash (used in) provided by investing activities	−17	12	22	12	−48
Proceeds from issuance of preferred stock in connection with private placement, net of issuance costs	267	—	—	—	—
Proceeds from issuance of common stock in connection with stock option exercise	33,000	—	—	—	—
Net cash provided by financing activities	267	—	3	507,000	—
Net increase (decrease) in cash and cash equivalents	243	−7	−12	−30	−100
Effect of exchange rate changes on cash and cash equivalents	705,000	−317,000	384,000	264,000	−917,000
Cash paid for taxes	5,000	—	—	—	—
Fair value of the Series B Preferred Stock issued in connection with the Damora Asset Acquisition	153	—	—	—	—
Operating lease liability arising from obtaining right-of-use assets	—	75,000	—	488,000	411,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is Damora Therapeutics, Inc.'s CIK number?

Damora Therapeutics, Inc.'s SEC CIK number is 0001800315 (1800315). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find Damora Therapeutics, Inc.'s SEC filings?

All of Damora Therapeutics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did Damora Therapeutics, Inc. last report earnings?

Damora Therapeutics, Inc. (DMRA) most recently filed an earnings 8-K with the SEC on Mar 10, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001193125-26-099404). This is Damora Therapeutics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is Damora Therapeutics, Inc.'s most recent earnings 8-K?

Damora Therapeutics, Inc.'s latest earnings 8-K (Item 2.02) was filed Mar 10, 2026 under accession 0001193125-26-099404. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View Damora Therapeutics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →